MIAT is increased in patients with elevated circulating lipoprotein(a) levels. A, Expression of MIAT in patients in Biobank of Karolinska Endarterectomies with low (<20 mg/dL) and high (>60 mg/dL) lipoprotein(a) (Lp[a]) serum levels. B. Expression of MIAT in hCASMCs on Lp(a) stimulation. C and D, Proliferation (C) or apoptosis (D) of hCASMCs on MIAT knockdown (KD), Lp(a) or combined treatment monitored live-cell imaging over time (data were analyzed by 2-way ANOVA). E, Left, Schematic of APO(a) peptide constructs with (17K) or without (17KDelta) an attached oxidized phospholipid. E, Right, Expression of MIAT in hCASMCs on 17K or 17KDelta stimulation. F, Immunostaining of Ki-67 in hCASMCs with 17K or 17KDelta stimulation (white arrows indicate Ki-67–positive cells). Data were analyzed by Student t test (A), 2-way repeated-measures ANOVA (C), area under the curve (D), or 1-way ANOVA (B, E). *P<0.05; ***P<0.001; ****P<0.0001. Cas indicates caspase; ctrl, control; DAPI, 4′,6-diamidino-2-phenylindole; and Rel., relative.